RegulationPriority Review (United States), Accelerated Approval (United States), Orphan Drug (United States), Orphan Drug (European Union), Orphan Drug (Japan), Orphan Drug (Australia), Priority Review (Australia)

Structure/Sequence

Sequence Code 12981416H

Source: *****

Sequence Code 13030670L

Source: *****

Clinical Trials associated with Retifanlimab

NCT07765836

/ Not yet recruitingPhase 2IIT

A Phase 2 Study of Fc Enhanced checKpoint bLockade With CTLA4 Antibody Vilastobart in Combination With PD-1 antibodY RetifAnlimab in BRCA or PALB2 Deficient Pancreatic Adenocarcinoma (EKLAVYA-HRD)

This is a single arm, open-label, non-randomized multi-institution phase II trial of a Fc enhanced CTLA4 antibody, vilastobart, in combination with PD-1 antibody, retifanlimab, in patients with BRCA1, BRCA2 or PALB2 deficient pancreatic cancer (PC).

Start Date01 Jan 2027

Sponsor / Collaborator

The Massachusetts General Hospital

[+3]

NCT07772245

/ Not yet recruitingPhase 2IIT

Phase II Trial of Retifanlimab With Trastuzumab and Pertuzumab Combination in HER2-Addicted Breast Cancer

The goal of this Clinical Trial is to find out how well 3 medicines (retifanlimab, trastuzumab and pertuzumab) work at treating HER2-positive breast cancer in Male and female patients, 18 or older. The main question aims to determine the pathologic response rate [residual cancer burden (RCB)- 0] in the breast and lymph nodes after 6 cycles of retifanlimab, trastuzumab and pertuzumab in patients with HER2-addicted breast cancer. Participants will will have at least 6 cycles of the study drug, assuming the participant is responding to and tolerating the treatment well. Every cycle will last about 21 days.

Start Date31 Dec 2026

Sponsor / Collaborator

The Methodist Hospital Research Institute

NCT07472322

/ Not yet recruitingPhase 1/2IIT

UW26001 Phase I/II Study on the Safety, Tolerability, and Preliminary Efficacy of ASTX727 (Decitabine/Cedazuridine) and Retifanlimab-dlwr in Patients With Advanced Merkel Cell Carcinoma Who Have Progressed on Anti-PD-(L)1 Inhibitor

The goal of this clinical trial is to learn if ASTX727 can be combined with retifanlimab to treat Merkel cell cancer. It will also learn about the safety of combining these drugs. The main questions it aims to answer are:
* Can the combination shrink cancer and lower the chance of the cancer growing or spreading?
* Is the combination better than standard of care for Merkel cell cancer?
Participants will:
* Take oral ASTX727 and retifanlimab through a vein in the arm for about 2 years.
* Visit the clinic once every 2 weeks for checkups and tests

Start Date01 Sep 2026

Sponsor / Collaborator

University of Wisconsin-Madison

100 Clinical Results associated with Retifanlimab

100 Translational Medicine associated with Retifanlimab

100 Patents (Medical) associated with Retifanlimab

Literatures (Medical) associated with Retifanlimab

01 Aug 2026·ANNALS OF ONCOLOGY

Survival outcomes in POD1UM-303/InterAACT-2: a phase III study of retifanlimab plus carboplatin–paclitaxel in first-line advanced squamous anal cancer

Article

Author: Roy, A ; Lievre, A ; Rao, S ; Dahan, L ; Maurel, J ; Guimbaud, R ; Zhang, P ; Fakih, M ; Zampino, M G ; Evesque, L ; Samalin-Scalzi, E ; Munteanu, M C ; Dhadda, A S ; Takashima, A ; Spano, J ; Casanova, N ; Tamberi, S ; de la Fouchardiere, C ; Morano, F ; Ben Abdelghani, M ; Jones, M

BACKGROUND:

In the primary analysis of the POD1UM-303/InterAACT 2 trial, median progression-free survival (PFS) was significantly longer with retifanlimab plus carboplatin-paclitaxel than with placebo plus carboplatin-paclitaxel in adult, systemic treatment-naïve patients with advanced/metastatic squamous cell carcinoma of the anal canal (SCAC). In this article, the final overall survival (OS) data from PODIUM-303/InterAACT 2, along with subgroup and exploratory analyses, are presented.

PATIENTS AND METHODS:

POD1UM-303/InterAACT-2 was a phase III, randomized, double-blind, controlled, multicenter trial with an optional crossover period undertaken in Europe, Australia, Japan, the UK, and the United States. The primary endpoint was PFS, and OS was the key secondary endpoint. Other endpoints included response, safety, and exploratory subgroup analyses.

RESULTS:

A total of 308 patients were randomly assigned (n = 154 for each of the retifanlimab plus carboplatin-paclitaxel and placebo plus carboplatin-paclitaxel groups), and 77 patients in the placebo plus carboplatin-paclitaxel group crossed over to receive retifanlimab monotherapy. When retifanlimab plus carboplatin-paclitaxel was compared with placebo plus carboplatin-paclitaxel in the updated efficacy analysis, there was a continued PFS benefit [hazard ratio (HR) 0.62, 95% confidence interval (CI) 0.47-0.81, nominal P = 0.0002] and a consistent and clinically meaningful improvement in OS (HR 0.75, 95% CI 0.55-1.01, P = 0.0305); median OS was 32.8 versus 22.2 months. Overall response rate was 56.5% versus 44.8%, and disease control rates were 87.7% versus 80.5%. The results of the crossover-adjusted analysis were consistent with the main analysis, and there was a consistent OS benefit in favor of retifanlimab plus carboplatin-paclitaxel in all subgroups analyzed. No new safety signals or trends were reported.

CONCLUSION:

This final analysis confirms the benefits of retifanlimab plus chemotherapy in SCAC. The results suggest that retifanlimab represents a new reference treatment and standard of care for patients with inoperable, locally recurrent, or metastatic SCAC.

01 Aug 2026·ANNALS OF ONCOLOGY

Integration of retifanlimab into the standard of care first-line therapy of advanced squamous anal cancer—lessons learned and open questions

Author: Hofheinz, R-D ; Modest, D P

01 May 2026·Journal for ImmunoTherapy of Cancer

Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcoma

Article

Author: Biniakewitz, Matthew ; Gounder, Mrinal M ; Erinjeri, Joseph P ; Cho, Jae-Mun ; Desir, Rhoena ; Chi, Ping ; Lefkowitz, Robert A ; D’Angelo, Sandra ; Singer, Samuel ; Avutu, Viswatej ; Kelly, Ciara M ; Reed, Damon ; Movva, Sujana ; Banks, Lauren B ; Tap, William ; Koff, Andrew ; Keohan, Mary L ; Dickson, Mark A ; Seffar, Evan ; Duchemin, Michele ; Rosenbaum, Evan ; Gularte-Mérida, Rodrigo ; Seier, Kenneth ; Maki, Robert G ; Qin, Li-Xuan ; Chan, Jason E

Background:

The cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor palbociclib delays disease progression in dedifferentiated liposarcoma (DDLPS) by inducing tumor cell quiescence or senescence, though most tumors ultimately progress. Preclinical data suggest CDK4/6 inhibition enhances intratumoral inflammation and may synergize with immune checkpoint inhibitors.

Methods:

This non-randomized, open-label, phase 2 study was conducted at Memorial Sloan Kettering Cancer Center. Patients with metastatic or unresectable DDLPS, or those expected to benefit from systemic therapy prior to surgery, were eligible. Patients received palbociclib (125 mg orally, days 1–21 of a 28-day cycle) plus retifanlimab (500 mg intravenous flat dose every 4 weeks). The primary endpoint was to assess the best objective response rate (ORR) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.

Results:

30 patients were treated and evaluable. Median age was 61 years (range 36–81), 67% were male, and 63% were treatment-naive. The median follow-up was 14.8 months. ORR was 20% (95% CI 8% to 39%) and the clinical benefit rate was 53% (95% CI 34% to 72%). Median progression-free survival and overall survival were 4.8 (95% CI 1.71 to 15.7) and 27 months (95% CI 21.7 to not reached (NR)), respectively. Median duration of response was 18.4 months (95% CI 9.4 months to NR). Grade ≥3 treatment-related adverse events occurred in 61% of patients, including one Grade 4 neutropenia. There were no Grade 5 events. Retifanlimab and palbociclib were discontinued due to toxicity in 23% and 17% of patients, respectively. Tumor sequencing identified JUN amplification in 6 of 14 patients with progressive disease versus 2 patients with stable disease or partial response. Patients with progressive disease had a higher median copy number alteration burden compared with those with stable disease or partial response.

Conclusions:

Palbociclib plus retifanlimab demonstrated deep and durable responses in a subset of patients with advanced DDLPS, with an ORR exceeding that historically observed with either agent alone. Adverse events were generally manageable. Copy number alteration burden and JUN amplification merit further evaluation as potential biomarkers of resistance.

Trial registration number:

https://clinicaltrials.gov/study/NCT04438824 .

167

News (Medical) associated with Retifanlimab

17 Sep 2026

·www.biospace.com

A2 Biotherapeutics Presents Early Safety and Efficacy Data from the DENALI-1 Study of A2B395, Highlighting First Reported Case of Complete Response to CAR T-Cell Therapy in Anal Cancer and Partial Response at 6 Months in Refractory Head & Neck Cancer

Ne ither patient experienced serious adverse events following treatment in DENALI-1 with A2B395, an EGFR-targeted allogeneic CAR T-cell therapy Poster presentation during the 2026 Cell Coast Conference details findings on first ten adult patients with previously treated EGFR-positive advanced solid tumors treated in DENALI-1 Findings from DENALI-1 study underscore previously reported complete response to CAR T-cell therapy in non-small cell lung cancer patient in separate study using the Tmod TM platform AGOURA HILLS, Calif.--(BUSINESS WIRE)-- #A2B395 --A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage immunotherapy company developing first-in-class logic-gated therapies for solid tumors, today announced early safety and efficacy data from the ongoing DENALI-1 clinical study ( NCT06682793 ). The study evaluates A2B395, an allogeneic, logic-gated chimeric antigen receptor T-cell (CAR T-cell) therapy targeting EGFR, developed based on the company’s proprietary Tmod TM platform. The findings include the first reported complete response (CR) in a patient with metastatic anal cancer, and a partial response with disease control for six months in a patient with refractory head and neck squamous cell cancer (HNSCC) following treatment with A2B395. This data is being presented in a poster presentation during the 2026 Cell Coast Conference taking place October 9 - 11, 2026, in Tampa, Florida. DENALI-1 is a first-in-human, open-label, Phase 1/2 study evaluating the safety and recommended Phase 2 dose of A2B395 in adults with previously treated EGFR-positive advanced solid tumors. DENALI-1 is currently enrolling patients with recurrent unresectable, locally advanced, or metastatic solid tumors associated with EGFR expression. Few treatment advancements have been made for anal cancer. Standard EGFR-targeted therapies can cause severe toxicities, 1 and surgical treatments can impact a patient’s quality of life. Head and neck cancers are the seventh most common cancer worldwide, and high rates of morbidity and mortality are associated with this disease. 2 According to the latest GLOBOCAN estimates (2020), HNSCC accounts for an estimated 890,000 new cases, or approximately 4.5% of all cancer diagnoses around the world, and 450,000 deaths per year, or approximately 4.6% of global cancer deaths. 3 Complete responses have rarely been observed in studies of CAR T-cell therapies for the treatment of solid tumors, and to date none has been reported in patients with anal cancer. 4 “We are deeply encouraged by the DENALI-1 study data being presented during the Cell Coast Conference, notably the first reported complete response in a patient with anal squamous cell carcinoma treated at our institution. This patient had previously undergone multiple lines of chemotherapy, retifanlimab, and radiation, before receiving A2B395, an allogeneic CAR T-cell therapy built on the Tmod platform, and experienced minimal toxicity. These early findings support the potential for A2B395 to treat patients with solid tumors expressing EGFR,” said Kedar Kirtane, M.D., Medical Director for Solid Tumor Cellular Therapy at Moffitt Cancer Center and the principal investigator who oversaw the treatment of the patient. “Our head and neck cancer patient had previously received several lines of therapy for a painful, softball-size tumor in their neck and had no response to any of those other treatments. After receiving A2B395, pain from the tumor resolved and the tumor shrank enough to allow them to return to work, and it is the first time since diagnosis to not be receiving regular chemotherapy doses. The partial response and minimal toxicity from the treatment resulted in a profound improvement of the patient’s quality of life,” said Matthew Ulrickson, M.D., Chief, Section of Hematology, Banner MD Anderson Cancer Center. “Recent results from our DENALI-1 and EVEREST-2 ( NCT06051695 ) clinical trials provide exciting early evidence of safety and efficacy. Following a single dose of A2B395, we saw heavily pre-treated patients with refractory anal cancer and head and neck cancer respectively achieve a complete response and a partial response. Importantly, both patients experienced no serious adverse events. We previously reported similar outcomes with the MSLN-targeted autologous CAR T-cell therapy, A2B694, including a complete response by central review in a patient with refractory lung cancer. Together, these results provide encouraging early proof-of-concept that our Tmod logic-gated CAR T platform – both autologous and allogeneic approaches – can safely treat difficult solid tumors,” said John Welch, M.D., Ph.D., Chief Medical Officer, A2 Bio. Summary of DENALI-1 Study Findings As of August 1, 2026, 10 patients received A2B395 for advanced solid tumors: anal (n=1); head and neck squamous cell (HNSCC; n=1); non-small cell lung (n=2); colorectal (n=3); and breast (n=3). The median patient age is 56 (range 33-70) years, and 80 percent enrolled are women. Dose levels (DLs) were 2×10 8 (n=3), 4×10 8 (n=4), and 8×10 8 (n=3) cells. Safety: Lymphodepletion was well-tolerated with anticipated, transient cytopenias. No graft-versus-host disease, immune effector cell-associated neurotoxicity syndrome (ICANS), dose-limiting toxicities (DLTs), immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome, or fatal adverse events were reported. Two patients had grade 1/2 cytokine release syndrome that fully resolved. Efficacy: Nine patients were evaluable for efficacy. The patient with unresectable anal cancer, after five different chemotherapy regimens and two rounds of radiation treatment, received A2B395 (DL3) and achieved a complete response (CR) on Day 28, with complete resolution of all target and non-target lesions and no serious adverse events. The patient with HNSCC (DL2) achieved a confirmed partial response (PR) on Day 180, after a 37% reduction in 3 target lesions, the largest which was 7.7 cm prior to receiving A2B395. Remaining best responses were stable disease (n=5) and progressive disease (n=2), resulting in a 78% disease control rate. Translational: A2B395 was detectable in blood and biopsies across all dose levels. About DENALI-1 DENALI-1 ( NCT06682793 ) is a phase 1/2, multicenter, open-label, nonrandomized study evaluating the safety and efficacy of A2B395, an allogeneic logic-gated Tmod™ CAR T-cell therapy, in adults. Patients are enrolled through BASECAMP-1 ( NCT04981119 ), a master prescreening study that identifies patients with HLA LOH at any time in the course of their disease via next-generation sequencing. Upon disease progression the participant may screen for enrollment in DENALI-1. A2B395 uses a Tmod logic-gate: an activator targeting EGFR and a blocker targeting HLA-A*02. In patients with HLA-A*02 loss of heterozygosity (LOH), the blocker inhibits both CAR and endogenous T-cell receptor (TCR) activity on normal tissue, providing tumor selectivity without gene editing, reducing on-target, off-tumor toxicity, and mitigating graft-versus-host disease. DENALI-1 is currently enrolling patients with recurrent unresectable, locally advanced, or metastatic colorectal, non-small cell lung, triple-negative breast, head and neck squamous cell, and renal cell cancer, cholangiocarcinoma, and cancer of unknown primary or other solid tumors associated with EGFR expression. Patients are not required to undergo leukapheresis to receive treatment on DENALI-1 because A2B395 is an allogeneic treatment. More information about DENALI-1 and clinical trial sites participating in the study are available on the A2 Bio clinical trials website . About the Tmod™ Platform Invented at A2 Bio, the Tmod TM platform is a precision-targeting cellular system, designed with logic-gate technology to enable immune cells to unequivocally differentiate tumors from normal tissues. The system consists of activator and blocker receptors. The activator recognizes antigens on tumor cells and triggers their destruction, while the blocker recognizes antigens on normal cells and protects them. This novel blocker technology enables precise, personalized, and effective T-cell targeting specifically against tumors. For more information about A2 Bio clinical studies and how to enroll, visit . About A2 Bio A2 Biotherapeutics, Inc. (A2 Bio) is a clinical-stage biotech company developing first-in-class logic-gated cell therapies to address the high unmet need in cancers. A2 Bio invented the proprietary Tmod™ cell therapy platform to tackle the fundamental challenge in cancer treatment—the ability of cancer medicines to distinguish between tumor and normal cells. For more information, visit the company’s website at . References 1 Macdonald JB, et al. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane. J Am Acad Dermatol. 2015;72:203-218. doi: 10.1016/j.jaad.2014.07.032. 2 Kirtane K, et al. Am Soc Clin Oncol Educ Book 46. 2026;e516922. doi: 10.1200/EDBK-26-516922. 3 Barsouk A, et al. Epidemiology, Risk Factors, and Prevention of Head and Neck Squamous Cell Carcinoma. Med Sci (Basel). 2023;11:42. doi: 10.3390/medsci11020042. 4 Escobar G, et al. CAR-T cells in solid tumors: Challenges and breakthroughs. Cell Reports Medicine. 2025;6;102353. doi: j.xcrm.2025.102353. Contacts Mary-Frances Faraji Jeff Winton Associates maryfrances@jeffwintonassociates.com 908-334-7693

20 Aug 2026

·www.prnewswire.com

The Lustgarten Foundation Announces New Pancreatic Cancer Research Funding Totaling $22.8 Million In Fiscal Year 2026

The Foundation increased its new research funding by $8.6M, year over year. UNIONDALE, N.Y., Aug. 20, 2026 /PRNewswire/ -- The Lustgarten Foundation, the world's largest private funder of pancreatic cancer research, today announced $22.8 million in new research funding in fiscal year 2026, an increase of $8.6 million compared with the previous year. The new funding supports 18 research projects advancing innovative approaches to early detection and interception, therapeutics development, and personalized medicine, with the potential to accelerate discoveries that could change how pancreatic cancer is detected and treated. "For decades, the Lustgarten Foundation has recognized that transforming pancreatic cancer requires bold, sustained investment in science," said Linda Tantawi, CEO of the Lustgarten Foundation. "Today, pancreatic cancer research is entering a period of unprecedented momentum, driven by discoveries that are reshaping what is possible for patients. As the research community faces increasing uncertainty and funding challenges, the Foundation remains committed to protecting that progress by expanding our investment in the ideas, investigators, and collaborations that will carry these breakthroughs forward." INVESTING ACROSS THE RESEARCH PIPELINE The Lustgarten Foundation's research strategy is designed to investigate every stage of pancreatic cancer, from preventing or intercepting the disease before it develops to bringing new therapies to patients faster. Of the 62 total active research grants supported: 14% supports early detection and interception research, developing technologies and biomarkers to identify pancreatic cancer earlier and improve screening for high-risk individuals. 66% supports therapeutics development, accelerating discoveries from the laboratory into innovative therapies and clinical trials. 20% supports personalized medicine, helping researchers better understand the biology and diversity of pancreatic cancer so treatments can be matched to the patients most likely to benefit. Accelerating Clinical Research The Dr. Robert F. Vizza Lustgarten Clinical Accelerator Initiative (CAI) is an innovative program designed to rapidly translate promising laboratory discoveries into science-driven clinical trials. Grants were awarded to: Ashwin Somasundaram, MD, University of North Carolina, for his study "A randomized, phase II study of subjects with advanced basal-like pancreatic adenocarcinoma treated with a KRAS G12D inhibitor and erlotinib versus gemcitabine and nab-paclitaxel." Somasundaram's team will evaluate a more personalized treatment approach for an aggressive subtype of pancreatic cancer by using a novel test to identify eligible patients and comparing a targeted drug combination with standard chemotherapy. Harshabad Singh, MBBS, MD, Mass General Brigham Cancer Institute, for his study "A phase 2 trial of a novel Fc enhanced CTLA4 antibody, Vilastobart, in combination with PD-1 inhibitor, Retifanlimab, in BRCA/PALB2 mutated pancreatic cancers." Singh's team will investigate a novel immunotherapy combination for patients with metastatic pancreatic cancer whose tumors carry BRCA1, BRCA2, or PALB2 mutations, while studying biological markers to identify those most likely to benefit. Mark O'Hara, MD, University of Pennsylvania, for his study "Phase I randomized control trial of gemcitabine and nab-paclitaxel with or without sotigalimab in a biomarker-selected population of previously untreated metastatic pancreatic cancer." O'Hara's team will investigate whether a simple blood test can identify patients with untreated metastatic pancreatic cancer who are most likely to benefit from adding immunotherapy to standard chemotherapy. Anirban Maitra, MD, NYU Langone Health's Perlmutter Cancer Center, for his study "A First-in-Human Trial of Pancreatic Cancer Interception by Targeting Mutant KRAS." Maitra and Team iPACK will evaluate a first-of-its-kind pancreatic cancer prevention strategy by testing whether an oral KRAS inhibitor can safely target precancerous pancreatic cysts with KRAS mutations before they progress to cancer. The Lustgarten Equity, Accessibility, and Diversity (LEAD) Project supports efforts to increase recruitment and retention in pancreatic cancer clinical trials. This year's grant was awarded to: Rebecca Snyder, MD, MPH, and co-investigator Heather G. Lyu, MD, MBI, The University of Texas MD Anderson Cancer Center, for their study "TrialScribe: Scalable and Transparent Pancreatic Cancer Clinical Trial Matching." Synder and Lyu's team will harness the power of artificial intelligence to make clinical trial enrollment more efficient, consistent, and equitable for pancreatic cancer patients. Pancreatic Adenocarcinoma Signature Stratification for Treatment (PASS-01) demonstrated how collaborative, biomarker-driven clinical trials can accelerate progress in pancreatic cancer research and patient care. To further the trial's success, a grant was awarded to: Mari Nakazawa, MD, Johns Hopkins Medicine, for her study "Establishing a Multi-Institutional Consortium (PASS-02) for Translational Clinical Trials in Locally Advanced Pancreatic Cancer." Nakazawa's team will build on the success of PASS-01 by establishing a multi-institutional consortium to advance biomarker-driven clinical trials and precision medicine approaches for patients with locally advanced pancreatic cancer (LAPC). A hallmark of the Lustgarten Foundation's unique research strategy, the LABS (Lustgarten Advancing Breakthrough Science) Program, provides long-term funding to promote the development of innovative ideas and speed the pace of discovery by incentivizing interdisciplinary team science. The Foundation supports six LABS sites across the country and this year renewed its commitment to: Reuben Shaw, PhD, led LABS Program site at the Salk Institute for Biological Studies, launched in 2021, focusing on decoding new targets for pancreatic cancer therapeutics. Investing in the Next Generation of Scientific Leaders. The Lustgarten Foundation–AACR Career Development Awards, honoring Ruth Bader Ginsburg and John Robert Lewis, support promising early-career investigators pursuing bold ideas in pancreatic cancer research. Grants were awarded to: Sandra Misale, PhD, John Hopkins University, for her study "HER2 targeting in KRAS mutant pancreatic ductal adenocarcinoma." Misale's team will investigate why some pancreatic cancers become resistant to KRAS inhibitors and identify combination treatment strategies that could improve and extend patient responses. Dig B. Mahat, PhD, Columbia University, for his study "Targeting immune cell enhancers propagating immunosuppression in pancreatic ductal adenocarcinoma." Mahat's team will investigate how immune cells enable pancreatic tumors to evade the body's immune system. The Lustgarten Foundation Innovation and Collaboration Program provides seed funding for innovative research with the potential to accelerate pancreatic cancer research, attracting new talent and advancing novel approaches to the field. Grants were awarded to: Cosimo Commisso, PhD, Sanford Burnham Prebys Medical Discovery Institute, for his project, "Macropinocytosis: A Paradigm Shift from Metabolic Inhibition to Lethal Hyper-Activation in PDAC." Commisso's team will investigate a first-of-its-kind strategy that exploits pancreatic cancer cells' nutrient-scavenging process to trigger cancer cell death and improve the delivery of chemotherapy. Jonathan Serody, MD, and co-investigators Jen Jen Yeh, MD, UNC Lineberger Comprehensive Cancer Center, and Sarah Shelton, PhD, NC State University, and for their project, "Enhancing Metabolic T cell Fitness for Adoptive Cell Therapy for Pancreatic Cancer Using Novel Microfluidic Chips." Serody's team will develop and evaluate metabolically enhanced CAR-T cells that can better survive within pancreatic tumors. Driving Progress Through Collaboration The Lustgarten Foundation joined forces with leading cancer research organizations - The Mark Foundation for Cancer Research, the American Association for Cancer Research (AACR), Break Through Cancer, and The Honorable Tina Brozman Foundation (Tina's Wish) - to launch a coalition to accelerate the early detection of deadly cancers, a shared effort focused on one of oncology's most urgent challenges: detecting cancer earlier, when treatment can still change outcomes. Early detection in pancreatic cancer grants were awarded to: Nikolaos G. Sgourakis, PhD, Children's Hospital of Philadelphia and University of Pennsylvania, Mark A. Sellmyer, MD, PhD, University of Pennsylvania, and Possu Huang, PhD, Stanford University, for their study "Programmable Recognition of KRAS Neoantigens for Early Cancer Diagnostics Across Patients." The team will investigate whether a molecular biomarker that is elevated in many cancer cells but largely absent from healthy tissue, can be used to detect pancreatic cancer, as well as breast and ovarian, earlier, identify tumors at risk of progression, and guide targeted treatment approaches. Brian M. Wolpin, MD, MPH, Dana-Farber Cancer Institute, Andrew J. Aguirre, MD, PhD, Dana-Farber Cancer Institute, Julie L. Sutcliffe, PhD, University of California, Davis, and Laura D. Wood, MD, PhD, Johns Hopkins University, for their study "Detection and Interception of KRAS-mutant Pancreatic Cancer Using Small Molecule RAS(ON) Inhibitors." The team will develop a molecular imaging probe that recognizes cancer-specific KRAS mutation signals on tumor cells, with the goal of detecting pancreatic cancer earlier and improving future treatment decisions. Now in its fourth year, the Lustgarten Foundation–Break Through Cancer Conquering KRAS in Pancreatic Cancer TeamLab continues to drive one of the field's most ambitious collaborative efforts to overcome mutated KRAS, the genetic driver of more than 90% of pancreatic cancers. Building on discoveries from the first phase of the initiative, the Lustgarten Foundation recommitted support for this multidisciplinary team of scientists and clinicians from six leading cancer centers. Innovative approaches to Early Detection Pancreatic cancer often progresses silently and aggressively, with symptoms appearing only after it has advanced, when treatment options are few and outcomes are poor — earlier detection remains our single greatest opportunity to improve patient outcomes. To explore the subtle changes that occur in the body as pancreatic cancer develops, grants were awarded to: Matthew Vander Heiden, MD, PhD, Massachusetts Institute of Technology, for his study "Understanding how pancreatic cancer impacts pancreas function to enable earlier cancer detection." Vander Heiden's team will study how early pancreatic cancer disrupts the normal functions of the pancreas and alters the body's metabolism. David Ting, MD, PhD, Mass General Brigham, for his study "Decoding Dark-Matter Humoral Immunity in Pancreatic Cancer." Ting's team will investigate how the immune system responds to normally silent genetic elements that become activated in pancreatic cancer by developing a blood-based test. Elliot Fishman, MD, Johns Hopkins Medicine, for his study "Felix 2.0: The Earlier Detection of Pancreatic Cancer and the Role of Imaging in its Detection and Management." Fishman's team will build on previous learnings by using AI-driven imaging analysis to identify early pancreatic cancers and precancerous lesions by extracting imaging features that improve detection of small abnormalities and support more accurate clinical decision-making. Understanding Treatment Response and Resistance Pancreatic cancer is particularly difficult to treat because tumors can adapt to therapy and develop resistance, allowing cancer cells to survive and continue growing. To better understand the factors that determine response and resistance, a grant was awarded to: Gregory Beatty, MD, PhD, University of Pennsylvania, for his study "Deciphering elements that determine immunotherapy efficacy in pancreatic cancer." Beatty's team will investigate why some pancreatic cancers respond to immunotherapy while others become resistant by analyzing tumor and immune factors that influence treatment response. LEADING THE WAY With these latest awards, the Lustgarten Foundation has invested $333 million in pancreatic cancer research across 386 projects at 86 academic institutions, since its founding in 1998. The Foundation drives scientific breakthroughs that are redefining what is possible for patients and bringing the field closer than ever to transforming pancreatic cancer into a curable disease. About The Lustgarten Foundation The Lustgarten Foundation is the largest private funder of pancreatic cancer research in the world, funding preeminent pancreatic cancer research, driving the pursuit of bold and innovative science toward earlier detection and better treatments, and transforming pancreatic cancer into a curable disease. The Foundation funds research where creative risks yield high rewards to accelerate and expand life-saving treatment options. We believe time is everything to patients and their families, and that community is power. Lustgarten programs and events provide people affected by pancreatic cancer a voice and a place to create hope, together. For more information about the Lustgarten Foundation, visit lustgarten.org and follow us on Facebook, Instagram, Bluesky, LinkedIn, and YouTube. SOURCE Lustgarten Foundation 21% more press release views with Request a Demo

Phase 2Immunotherapy

19 Aug 2026

·www.biospace.com

MacroGenics Reports Second Quarter 2026 Financial Results, Streamlined Operating Model and Strengthened Financial Position

Announced sale of manufacturing operations (July 2026) for $122.5 million and transition to fully outsourced model with leaner, approximately 140-person workforce focused on novel therapeutics pipeline Data presentations at ESMO planned for MGC026 (B7-H3 ADC) and lorigerlimab (PD-1 × CTLA-4) MGC028 (ADAM9 ADC) dose escalation study ongoing; disclosure of preliminary clinical results planned for late 2026 MGC030 IND application submission cleared ahead of schedule, with first patient expected to be dosed in third quarter Pro forma cash, cash equivalents and marketable securities of $327 million; cash runway guidance through 2028 ROCKVILLE, Md., Aug. 13, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today reported financial results for the quarter ended June 30, 2026, and highlighted its recent corporate and pipeline progress. “Our team delivered strong second-quarter execution: advancing our strategic priorities, strengthening our financial position, and sharpening our focus to accelerate the development of life-changing medicines for patients,” said Eric Risser, President and Chief Executive Officer of MacroGenics. “With a significantly stronger financial foundation, we are well-positioned to advance our pipeline and deliver a catalyst-rich period ahead.” Advancement of Innovative Pipeline MacroGenics is developing a portfolio of investigational agents, including both topoisomerase I inhibitor-based antibody-drug conjugates (ADCs) and T-cell engagers (TCEs). MGC026 is a novel ADC targeting B7-H3, a protein expressed across the tumor microenvironment, including tumor-associated stroma and vasculature. The dose-escalation portion of the ongoing Phase 1 study has been completed after evaluating doses ranging from 1 mg/kg to 9 mg/kg every three weeks (Q3W). A dose of 7.5 mg/kg Q3W is being further evaluated in four tumor-specific cohorts, including squamous cell carcinoma of the head and neck (SCCHN), endometrial cancer, melanoma and soft tissue sarcoma. MGC026 recently achieved an important milestone, with the SCCHN cohort meeting the pre-specified response threshold to advance into Stage 2. Interim results from the Phase 1 study have been accepted for poster presentation at the European Society for Medical Oncology (ESMO) 2026 Congress in October. MGC028 is a first-in-class ADC targeting ADAM9, a protein that is overexpressed in multiple solid tumors. The dose escalation study of MGC028 is ongoing and the Company anticipates providing an update with preliminary clinical results in late 2026. MGC030 is a first-in-class ADC targeting an undisclosed antigen expressed across several solid tumors. The Company’s Investigational New Drug (IND) application was submitted ahead of schedule and cleared by the U.S. Food and Drug Administration (FDA) in the second quarter of 2026. The Company plans to commence a Phase 1 dose escalation study in the third quarter of 2026. Lorigerlimab is a PD-1 × CTLA-4 bispecific DART® molecule being evaluated in patients with advanced gynecologic cancers. MacroGenics continues the Phase 2 LINNET study of lorigerlimab, with the interim data accepted for poster presentation at the ESMO 2026 Congress. The Company is enrolling 20 additional patients with clear cell gynecologic cancer (CCGC) at a dose of 3 mg/kg Q3W and anticipates reporting updated study results in the first half of 2027. Future Pipeline MacroGenics is advancing multiple preclinical programs that incorporate proprietary platforms for next-generation TCEs and ADCs. Following completion of preclinical proof-of-concept studies and preliminary toxicology in non-human primates, the Company recently nominated MGD032, a novel next-generation TCE against an undisclosed target. This molecule is now advancing in IND-enabling studies. Partnership Updates MacroGenics maintains partnerships with Incyte Corporation, Sanofi and Gilead Sciences, Inc. spanning multiple commercial, clinical and preclinical programs. Through these collaborations, the Company remains eligible to receive up to approximately $2.4 billion in aggregate future milestone payments, in addition to potential royalties on net product sales. On August 11, the Company announced that Gilead had exercised its option to license a preclinical bispecific program under the companies’ 2022 collaboration agreement. This option exercise triggers a $10.0 million payment to MacroGenics. The Company remains eligible to earn additional milestones and royalties based on net product sales. Corporate Update Corporate Restructuring and Divestiture of Manufacturing Operations . In July, MacroGenics announced the completion of the sale of its GMP drug substance manufacturing operations to Bora Pharmaceuticals Co., Ltd. and Bora Biologics USA, LLC (collectively, Bora) for a previously disclosed base purchase price of $122.5 million. At closing, the Company received $119.6 million in cash consideration, reflecting adjustments for net working capital and indebtedness, before transaction fees and expenses. Approximately 140 previous MacroGenics employees were hired by Bora and, together with a concurrent restructuring, MacroGenics’ workforce is anticipated to be reduced to approximately 140 employees by year-end. As part of the transaction, MacroGenics entered into a supply agreement with Bora to support process development and drug substance production for the Company’s internal pipeline. MacroGenics’ transition to a fully-outsourced manufacturing model and a leaner organization is expected to enable greater focus on the advancement of its novel therapeutics pipeline, while providing increased flexibility and cost effectiveness. Second Quarter 2026 Financial Results Cash Position : Cash, cash equivalents and marketable securities as of June 30, 2026, were $173.3 million, compared with $189.9 million as of December 31, 2025. The balance as of June 30, 2026, included $60.0 million received from Sagard Healthcare Partners related to the monetization of ZYNYZ® royalties. During the quarter, the Company also earned a $24.5 million regulatory milestone from Sanofi related to a U.S. approval of TZIELD®, with payment expected in the third quarter of 2026. Subsequent to June 30, 2026, MacroGenics received cash consideration of $119.6 million from Bora in connection with the completed sale of the Company’s GMP manufacturing operations. In addition, in August, the Company achieved a $10.0 million milestone pursuant to Gilead’s exercise of its option to obtain an exclusive license for a preclinical bispecific program under the companies’ 2022 collaboration agreement. The Company’s pro forma cash, cash equivalents and marketable securities as of June 30, 2026, including net proceeds from Bora, Sanofi and Gilead, totaled $327 million. Revenue : Total revenue was $32.8 million for the quarter ended June 30, 2026, compared with $6.9 million for the quarter ended June 30, 2025. The increase was primarily due to achievement of the $24.5 million regulatory milestone from Sanofi related to U.S. approval of TZIELD. R&D Expenses : Research and development expenses were $38.8 million for the quarter ended June 30, 2026, compared with $40.8 million for the quarter ended June 30, 2025. The decrease was primarily due to decreased costs related to lorigerlimab and discontinued programs, partially offset by increased trial costs related to MGC026 and MGC028. G&A Expenses : General and administrative expenses were $7.9 million for the quarter ended June 30, 2026, compared with $9.3 million for the quarter ended June 30, 2025. The decrease was primarily due to lower personnel-related costs, including stock-based compensation expense. Net Income (Loss) : Net income was $19.5 million for the quarter ended June 30, 2026, compared with net loss of $36.3 million for the quarter ended June 30, 2025. Net income for the quarter ended June 30, 2026, reflects income from discontinued operations of $89.2 million related to the sale of the Company's GMP manufacturing operations to Bora, and a $52.8 million non-cash loss on the extinguishment of the ZYNYZ royalty monetization liability. Shares Outstanding : Shares of common stock outstanding as of June 30, 2026, were 63,645,711. Cash Runway Guidance : MacroGenics anticipates that its pro forma cash, cash equivalents and marketable securities of $327 million as of June 30, 2026, plus other projected future payments from partners, will support the Company’s cash runway through 2028. MACROGENICS, INC. SELECTED CONSOLIDATED BALANCE SHEET DATA (Amounts in thousands) June 30, 2026 December 31, 2025 (unaudited) Cash, cash equivalents and marketable securities $ 173,305 $ 189,913 Total assets 345,409 256,846 Deferred revenue 55,503 56,779 Total stockholders' equity 42,873 55,591 MACROGENICS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) (Unaudited) (Amounts in thousands, except share and per share data) Three Months Ended June 30, Six Months Ended June 30, 2026 2025 2026 2025 Revenues: Collaborative and other agreements $ 25,488 $ 5,558 $ 26,058 $ 12,157 Royalty revenue 7,344 1,311 13,495 1,754 Total revenues 32,832 6,869 39,553 13,911 Costs and expenses: Research and development 38,780 40,791 73,754 80,489 General and administrative 7,904 9,302 17,614 20,020 Total costs and expenses 46,684 50,093 91,368 100,509 Loss from operations (13,852 ) (43,224 ) (51,815 ) (86,598 ) Loss on extinguishment of royalty monetization (52,762 ) — (52,762 ) — Interest and other income 1,368 1,414 2,922 3,093 Interest and other expense (4,396 ) (802 ) (9,285 ) (894 ) Loss before income taxes (69,642 ) (42,612 ) (110,940 ) (84,399 ) Income tax provision — 105 — 105 Net loss from continuing operations (69,642 ) (42,717 ) (110,940 ) (84,504 ) Net income from discontinued operations, net of taxes 89,157 6,466 93,681 7,217 Net income (loss) 19,515 (36,251 ) (17,259 ) (77,287 ) Other comprehensive income (loss): Unrealized gain (loss) on investments 12 (6 ) (47 ) (12 ) Comprehensive income (loss) $ 19,527 $ (36,257 ) $ (17,306 ) $ (77,299 ) Net income (loss) per common share - basic Net loss from continuing operations $ (1.10 ) $ (0.67 ) $ (1.75 ) $ (1.34 ) Net income from discontinued operations 1.40 0.10 1.47 0.11 Net income (loss) per share - basic $ 0.31 $ (0.57 ) $ (0.27 ) $ (1.23 ) Net income (loss) per common share - diluted Net loss from continuing operations $ (1.10 ) $ (0.67 ) $ (1.75 ) $ (1.34 ) Net income from discontinued operations 1.40 0.10 1.47 0.11 Net income (loss) per share - diluted $ 0.31 $ (0.57 ) $ (0.27 ) $ (1.23 ) Weighted average common shares outstanding Basic and diluted 63,594,453 63,136,057 63,522,516 63,051,207 About MacroGenics, Inc. MacroGenics (the Company) is a biopharmaceutical company focused on developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at MacroGenics, the MacroGenics logo, and DART are trademarks or registered trademarks of MacroGenics, Inc. Cautionary Note on Forward-Looking Statements Any statements in this press release about future expectations, plans and prospects for MacroGenics (“Company”), including statements about the Company’s strategy, future operations, clinical development of and regulatory plans for the Company’s therapeutic candidates, expected timing of the release of clinical updates and safety and efficacy data for the Company’s ongoing clinical trials, anticipated cash runway and other statements containing the words “subject to”, "believe", “anticipate”, “plan”, “expect”, “intend”, “estimate”, “potential”, “project”, “may”, “will”, “should”, “would”, “could”, “can”, the negatives thereof, variations thereon and similar expressions, or by discussions of strategy, including our ability to execute on our key strategic priorities for 2026, constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: risks related to the reproducibility of any results initially seen in any product candidate; risks that TZIELD, lorigerlimab, ZYNYZ, or any other product candidate’s revenue, expenses and costs may not be as expected; risks relating to TZIELD, lorigerlimab, ZYNYZ, or any other product candidate’s market acceptance, competition, reimbursement and regulatory actions; future data updates, including timing and results of efficacy and safety data with respect to product candidates in ongoing clinical trials; the uncertainties inherent in the initiation and enrollment of future clinical trials; the availability of financing to fund the internal development of our product candidates; expectations regarding the expansion of ongoing clinical trials; expectations for the timing and steps required in the regulatory review process; expectations for regulatory approvals; expectations of future milestone payments; the impact of competitive products; our ability to enter into agreements with strategic partners and other matters that could affect the availability or commercial potential of the Company's product candidates; business, economic or political disruptions due to catastrophes or other events, including natural disasters, terrorist attacks, civil unrest and actual or threatened armed conflict, or public health crises; costs of litigation and the failure to successfully defend lawsuits and other claims against us; risks related to the transition of the CDMO operations to the purchaser following the sale of our CDMO operations (the "Transaction"); risks related to the Company's post-closing manufacturing arrangements with the purchaser in the Transaction, including under the manufacturing and supply agreement and the transition services agreement; the possibility that the anticipated benefits of the Transaction may not be realized; and other risks described in the Company's filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views only as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof. CONTACTS Jim Karrels, Senior Vice President, CFO 1-301-251-5172 info@macrogenics.com Argot Partners 1-212-600-1902 macrogenics@argotpartners.com

Phase 1License out/inFinancial StatementPhase 2ADC

100 Deals associated with Retifanlimab

External Link

KEGG	Wiki	ATC	Drug Bank
D11827	-	-	DB15766

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Merkel Cell Carcinoma	United States	Incyte Corp.	30 Mar 2026
Anal canal squamous cell carcinoma	United States	Incyte Corp.	15 May 2025
Metastatic Merkel Cell Carcinoma	United States	Incyte Corp.	22 Mar 2023

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
squamous cell carcinoma of the anus	NDA/BLA	European Union	Incyte Biosciences Distribution BV	29 Jan 2026
Non-Small Cell Lung Cancer	NDA/BLA	United States	Incyte Corp.	-
Endometrial Carcinoma	Phase 3	China	Zai Lab (Shanghai) Co., Ltd.	20 Sep 2021
metastatic non-small cell lung cancer	Phase 3	China	Incyte Corp.	18 Sep 2020
metastatic non-small cell lung cancer	Phase 3	China	Zai Lab (Shanghai) Co., Ltd.	18 Sep 2020
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma	Phase 3	United States	Incyte Corp.	11 Sep 2020
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma	Phase 3	China	Incyte Corp.	11 Sep 2020
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma	Phase 3	Brazil	Incyte Corp.	11 Sep 2020
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma	Phase 3	Bulgaria	Incyte Corp.	11 Sep 2020
Metastatic Non-Squamous Non-Small Cell Lung Carcinoma	Phase 3	Czechia	Incyte Corp.	11 Sep 2020

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04370704 (CTgov)	Phase 1/2	Melanoma \| Metastatic melanoma \| Unresectable Melanoma	61	Tuparstobart+Verzistobart (Phase 1, Part 1: Tuparstobart 350 mg Q2W + Verzistobart 400 mg Q2W)	zmjabvyqfe = teawhoxeyg fpeouxcztq (tpyiyolgxg, ttmmnwebxk - uknovzeaor) View more	-	17 Aug 2026
				Tuparstobart+Verzistobart+Retifanlimab (Phase 1, Part 2: Tuparstobart 350 mg Q2W + Verzistobart 400 mg Q2W + Retifanlimab 500 mg Q4W)	zmjabvyqfe = heujibuglh fpeouxcztq (tpyiyolgxg, azhjtiogjh - zofuxulnrx) View more
NCT04438824 (Pubmed \| J Immunother Cancer)	Phase 2	Dedifferentiated Liposarcoma	30	RetifanlimabPalbociclib + RetifanlimabPalbociclibb	wqcqsvqnla(dkrxqxozhq) = npmdwovjhk ofzftxxetn (qugnjcpxnu, 8 - 39) View more	Positive	01 May 2026
NCT05287113 (CTgov)	Phase 2	Squamous Cell Carcinoma of Head and Neck \| PD-L1 positive Solid Tumors	176	Retifanlimab (Retifanlimab)	jchhoutflp(lwhpevjrak) = kfvwhfkcjp mkmvkuijwb (ujowtmpzzr, yehitogxya - evpfvtkaci) View more	-	27 Mar 2026
				Retifanlimab (Retifanlimab Plus INCAGN02385)	jchhoutflp(lwhpevjrak) = ihkyrjmrfx mkmvkuijwb (ujowtmpzzr, xtlatzhbnl - gjqwtkvocf) View more
NCT04438824 (Pubmed \| Cancer Res Commun)	Phase 2	Dedifferentiated Liposarcoma	12	Palbociclib and retifanlimab	inxsgxdsnf(eicxejmqhj) = mzqsybdjdg lyoevxaabc (pjaxsppiva ) View more	Positive	01 Feb 2026
NCT04472429 (POD1UM-303, ESMO_IO2025)	Phase 3	squamous cell carcinoma of the anus First line	308	Retifanlimab + carboplatin-paclitaxel	glsfpwxofq(rindmdakws) = yvhdcfqrmn sjlufhnrua (hpzovcykxi ) View more	Positive	12 Nov 2025
				Placebo + carboplatin-paclitaxel	glsfpwxofq(rindmdakws) = bqvuopzcrj sjlufhnrua (hpzovcykxi ) View more
EUCTR2021-005775-39-BE (ESMO2025)	Phase 2	PD-L1+	176	Retifanlimab (RETI)	kdqverzjin(aoyauyicjo) = thpubcrlio rcodipexjn (lhpcjahjgq, 3.5 - 9.7) View more	Negative	17 Oct 2025
				Retifanlimab + Tuparstobart (doublet tx)	kdqverzjin(aoyauyicjo) = dxuedegtme rcodipexjn (lhpcjahjgq, 3.7 - 7.6) View more
NCT04205812 (POD1UM-304, Pubmed) Manual	Phase 3	Non-Small Cell Lung Cancer First line	583	Retifanlimab + chemotherapy	ajrcrlweci(algetienmw) = makwfbqchj pupyqquymn (vzconujmbi, 16.2 - 21.0) View more	Positive	19 Sep 2025
				Placebo + chemotherapy	ajrcrlweci(algetienmw) = avqiszjrto pupyqquymn (vzconujmbi, 11.0 - 16.7) View more
NCT03532295 (CTIM-23, CTgov)	Phase 2	Glioblastoma Multiforme \| Glioblastoma \| Recurrent Glioblastoma	51	Radiation therapy+Bevacizumab+Retifanlimab (Regimen A: Retifanlimab+RT+bevacizumab)	qqwgpdwzht = jwdrevayix bppakvibdm (hxoujzmdag, zhhgmazmms - pykuzzbtsp) View more	-	07 Aug 2025
				Radiation therapy+Bevacizumab+Epacadostat+Retifanlimab (Regimen B: Retifanlimab+RT+bevacizumab+epacadostat)	qqwgpdwzht = odtekbpziq bppakvibdm (hxoujzmdag, fvgpwjbcmf - kbrstdgvdu) View more
NCT04116073 (CTgov)	Phase 2	Pancreatic carcinoma non-resectable	25	PD-1 antibody+INCMGA00012	fkhdurwdof = thlwnvvmfu jwmsglpdmz (qcwumfvvpt, gwyrfmwudz - yettnzyhdh) View more	-	29 Jul 2025
NCT05239182 (RiLEY, CTgov)	Phase 2	Pancreatic adenocarcinoma \| Pancreatic Ductal Adenocarcinoma \| Advanced Pancreatic Adenocarcinoma	7	9-ING-41+Abraxane+Gemcitabine+Retifanlimab	iddjmwetqs = brcfmadflr hdeuhyvqpg (nkvaipquhx, vacqhualii - rmnkvtlykb) View more	-	17 Jul 2025

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis